Acacia Research invests in intellectual property, and related absolute return assets and engages in the licensing and enforcement of patented technologies. The company partners with inventors and patent owners, from small entities to large corporations, applying its legal and technology capabilities to patent assets to unlock the financial value in their patented inventions. The company is an intermediary in the patent marketplace. The company has partnered with patent owners, including individual inventors, universities, small companies and large multi-national corporations in a variety of technology sectors.

CBTX is a bank holding company. Through its wholly-owned subsidiary, CommunityBank of Texas, N.A. (the Bank), the company focuses on providing commercial banking solutions to small and mid-sized businesses and personnel including attorneys, accountants and other service providers with operations in its markets. The Bank provides a range of banking products, including commercial and industrial loans, commercial real estate loans, construction and development loans, one-to-four family residential mortgage loans, multi-family residential loans consumer loans, agricultural loans, treasury services, retail deposits and a suite of online banking services.

Kewaunee Scientific is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. The company's products include steel, wood, and laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. The company's operations are classified into two business segments: Domestic, which designs, manufactures, and installs scientific and technical furniture; and International, which provides facility design, detailed engineering, construction, and project management.

Lexicon Pharmaceuticals is a biopharmaceutical company. The company is commercializing XERMELO? (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. The company is developing Zynquista? (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 2 diabetes. The company is also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease. The company is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.

Live Oak Bancshares is a bank holding company. Through its subsidiary, Live Oak Banking Company (the Bank), the company is engaged in providing lending and deposit related services. The company directly or indirectly holds the following wholly-owned subsidiaries: Canapi Advisors, LLC, which provides investment advisory services; Live Oak Ventures, Inc., which invests in businesses that align with the company's initiative in financial technology; Live Oak Grove, LLC, which provides an on-site restaurant location; Government Loan Solutions, Inc., which is a management and technology consulting firm; and 504 Fund Advisors, LLC, which serves as the investment advisor to the 504 Fund, a closed-end mutual fund.

Marrone Bio Innovations makes bio-based pest management and plant health products. Bio-based products are comprised of naturally occurring microorganisms, such as bacteria and fungi, and plant extracts. The company primarily sells its products to the crop protection market and also have one plant health product, Haven, that reduces plant stress in drought and intense sunlight. The company's product lines are Regalia, for controlling plant disease and increasing plant health, Grandevo and Venerate, for insect and mite control, Majestene and its turf and ornamentals counterpart brand Zelto, for nematode control and Stargus and its row crop counterpart brand Amplitude, for downy mildew and white mold control.

Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis (dialysis). Triferic? (ferric pyrophosphate citrate) is the company's proprietary iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. The company manufactures, sells, delivers and distributes hemodialysis concentrates, along with certain ancillary products. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream, which include CitraPure Citric Acid Concentrate.

Southern National Bancorp of Virginia is a bank holding company. Through its subsidiary, Sonabank, the company provides financial services to individuals and small and medium sized businesses. The company focuses on making loans secured primarily by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses, as well as loans to individuals. The company is a Small Business Administration lender. The company also invests in real estate-related securities, including collateralized mortgage obligations and agency mortgage backed securities. In addition, the company provides deposit products, including checking (NOW), savings, money market accounts and certificates of deposit.

vTv Therapeutics is a holding company. Through its subsidiaries, the company is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. The company's drug candidate for the treatment of Alzheimer's disease, azeliragon (TTP488), is an orally administered small molecule antagonist targeting the receptor for advanced glycation endproducts. The company's type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor. The company is also developing TTP399 for type 1 diabetes.